[424B5] Aptevo Therapeutics Inc Prospectus Supplement (Debt Securities)
Aptevo Therapeutics Inc. (NASDAQ: APVO) filed a prospectus supplement dated June 20, 2025 that updates its existing at-the-market (ATM) equity program with Roth Capital Partners. The supplement increases the remaining capacity available under the Form S-3 shelf registration to up to $8.04 million of additional common stock.
The adjustment reflects a rise in the company鈥檚 public float to $47.7 million (3,224,152 non-affiliate shares at $14.80 per share) as of June 20, 2025, which raises the one-third issuance limit permitted by General Instruction I.B.6 of Form S-3. During the prior 12-month period Aptevo already sold $7.87 million of stock under the ATM, leaving the newly disclosed capacity of $8.04 million before the 12-month ceiling of roughly $15.91 million is reached.
To date, the company has issued 481,828 shares for gross proceeds of $3.77 million at an average price of approximately $7.81 per share. The latest Nasdaq closing price was $4.17 (June 20, 2025), markedly below the $14.80 reference price used to calculate float, implying material dilution if additional shares are sold at current levels.
Aptevo cautions investors to review the risk factors in the original and prior prospectuses. No changes to use of proceeds or business strategy are disclosed; the document purely updates the share-sale capacity. Future supplements will be filed if the float increases sufficiently to permit higher issuance volumes.
Aptevo Therapeutics Inc. (NASDAQ: APVO) ha depositato un supplemento al prospetto datato 20 giugno 2025 che aggiorna il suo programma azionario at-the-market (ATM) esistente con Roth Capital Partners. Il supplemento aumenta la capacit脿 residua disponibile sotto la registrazione a scaffale Form S-3 fino a 8,04 milioni di dollari di azioni ordinarie aggiuntive.
L鈥檃deguamento riflette un aumento del flottante pubblico della societ脿 a 47,7 milioni di dollari (3.224.152 azioni non affiliate a 14,80 dollari per azione) al 20 giugno 2025, il che innalza il limite di emissione di un terzo consentito dall鈥橧struzione Generale I.B.6 del Form S-3. Nel periodo di 12 mesi precedente Aptevo ha gi脿 venduto azioni per un valore di 7,87 milioni di dollari nell鈥檃mbito dell鈥橝TM, lasciando una capacit脿 rimanente di 8,04 milioni di dollari prima di raggiungere il tetto annuale di circa 15,91 milioni di dollari.
Ad oggi, la societ脿 ha emesso 481.828 azioni per un ricavo lordo di 3,77 milioni di dollari a un prezzo medio di circa 7,81 dollari per azione. Il prezzo di chiusura pi霉 recente al Nasdaq 猫 stato di 4,17 dollari (20 giugno 2025), decisamente inferiore al prezzo di riferimento di 14,80 dollari usato per calcolare il flottante, implicando una diluizione significativa se ulteriori azioni venissero vendute ai livelli attuali.
Aptevo invita gli investitori a esaminare i fattori di rischio contenuti nel prospetto originale e in quelli precedenti. Non sono state apportate modifiche all鈥檜so dei proventi o alla strategia aziendale; il documento aggiorna esclusivamente la capacit脿 di vendita delle azioni. Ulteriori supplementi saranno depositati se il flottante aumenter脿 sufficientemente da consentire volumi di emissione maggiori.
Aptevo Therapeutics Inc. (NASDAQ: APVO) present贸 un suplemento al prospecto con fecha 20 de junio de 2025 que actualiza su programa de acciones at-the-market (ATM) existente con Roth Capital Partners. El suplemento incrementa la capacidad restante disponible bajo el registro en estanter铆a Formulario S-3 hasta 8,04 millones de d贸lares adicionales en acciones comunes.
Este ajuste refleja un aumento en el flotante p煤blico de la compa帽铆a a 47,7 millones de d贸lares (3.224.152 acciones no afiliadas a 14,80 d贸lares por acci贸n) al 20 de junio de 2025, lo que eleva el l铆mite de emisi贸n de un tercio permitido por la Instrucci贸n General I.B.6 del Formulario S-3. En los 12 meses anteriores, Aptevo ya vendi贸 acciones por un valor de 7,87 millones de d贸lares bajo el ATM, dejando una capacidad disponible de 8,04 millones de d贸lares antes de alcanzar el l铆mite anual aproximado de 15,91 millones de d贸lares.
Hasta la fecha, la empresa ha emitido 481.828 acciones para obtener ingresos brutos de 3,77 millones de d贸lares a un precio promedio de aproximadamente 7,81 d贸lares por acci贸n. El 煤ltimo precio de cierre en Nasdaq fue de 4,17 d贸lares (20 de junio de 2025), considerablemente por debajo del precio de referencia de 14,80 d贸lares utilizado para calcular el flotante, lo que implica una diluci贸n significativa si se venden m谩s acciones a los niveles actuales.
Aptevo advierte a los inversores que revisen los factores de riesgo en el prospecto original y en los anteriores. No se han divulgado cambios en el uso de los ingresos ni en la estrategia comercial; el documento solo actualiza la capacidad de venta de acciones. Se presentar谩n suplementos futuros si el flotante aumenta lo suficiente para permitir mayores vol煤menes de emisi贸n.
Aptevo Therapeutics Inc. (NASDAQ: APVO)電� 2025雲� 6鞗� 20鞚检瀽 韴瀽靹る獏靹� 氤挫订靹滊ゼ 鞝滌稖頃橃棳 Roth Capital Partners鞕�鞚� 旮办〈 ATM(At-the-Market) 欤检嫕 頂勲攴鸽灗鞚� 鞐呺嵃鞚错姼頄堨姷雼堧嫟. 鞚� 氤挫订靹滊姅 Form S-3 靹犽皹 霌彪 頃橃棎靹� 雮晞鞛堧姅 鞖╇焿鞚� 於旉皜 氤错喌欤� 斓滊寑 804毵� 雼煬旯岇 歃濌皜鞁滌及鞀惦媹雼�.
鞚� 臁办爼鞚� 2025雲� 6鞗� 20鞚� 旮办 須岇偓鞚� 瓿店皽 鞙犿喌 欤检嫕靾橁皜 4,770毵� 雼煬(牍勱硠鞐挫偓 欤检嫕 3,224,152欤�, 欤茧嫻 14.80雼煬)搿� 歃濌皜頄堨潓鞚� 氚橃榿頃橂┌, 鞚措姅 Form S-3鞚� 鞚茧皹 歆�旃� I.B.6鞐� 鞚橅暣 項堨毄霅� 1/3 氚滍枆 頃滊弰毳� 靸來枼鞁滍偟雼堧嫟. 歆�雮� 12臧滌洈 霃欖晥 Aptevo電� 鞚措 ATM鞚� 韱淀暣 787毵� 雼煬 靸侂嫻鞚� 欤检嫕鞚� 韺愲Г頄堨溂氅�, 鞚挫棎 霐半澕 12臧滌洈 頃滊弰 鞎� 1,591毵� 雼煬鞐� 霃勲嫭頃橁赴 鞝勱箤歆� 靸堧 瓿店皽霅� 鞖╇焿鞚� 804毵� 雼煬鞛呺媹雼�.
順勳灛旯岇 須岇偓電� 481,828欤�毳� 氚滍枆頃橃棳 齑� 377毵� 雼煬鞚� 靾橃澋鞚� 鞓牳鞙茧┌, 欤茧嫻 韽夑窢 臧�瓴╈潃 鞎� 7.81雼煬鞛呺媹雼�. 2025雲� 6鞗� 20鞚� 旮办 斓滉芳 雮橃姢雼� 膦呹皜電� 4.17雼煬搿�, 鞙犿喌 欤检嫕 瓿勳偘鞐� 靷毄霅� 旮办 臧�瓴� 14.80雼煬氤措嫟 順勳爛頌� 雮晞, 順勳灛 臧�瓴� 靾橃鞐愳劀 於旉皜 欤检嫕鞚� 韺愲Г霅� 瓴届毎 靸侂嫻頃� 頋劃 須臣臧� 鞓堨儊霅╇媹雼�.
Aptevo電� 韴瀽鞛愲摛鞐愱矊 鞗愲掣 氚� 鞚挫爠 韴瀽靹る獏靹滌棎 韽暔霅� 鞙勴棙 鞖旍唽毳� 瓴�韱犿暊 瓴冹潉 甓岅碃頃╇媹雼�. 靾橃澋 靷毄觳橂倶 靷梾 鞝勲灥鞐� 雽�頃� 氤�瓴� 靷暛鞚� 鞐嗢溂氅�, 鞚� 氍胳劀電� 雼 欤检嫕 韺愲Г 鞖╇焿鞚� 鞐呺嵃鞚错姼頃� 瓴冹瀰雼堧嫟. 頄ロ泟 鞙犿喌 欤检嫕鞚� 於╇秳頌� 歃濌皜頃橃棳 雿� 雴掛潃 氚滍枆霟夓澊 項堨毄霅橂┐ 於旉皜 氤挫订靹滉皜 鞝滌稖霅� 鞓堨爼鞛呺媹雼�.
Aptevo Therapeutics Inc. (NASDAQ : APVO) a d茅pos茅 un suppl茅ment au prospectus dat茅 du 20 juin 2025, mettant 脿 jour son programme d鈥檃ctions at-the-market (ATM) existant avec Roth Capital Partners. Ce suppl茅ment augmente la capacit茅 restante disponible dans le cadre de l鈥檈nregistrement sur 茅tag猫re Formulaire S-3 jusqu鈥櫭� 8,04 millions de dollars d鈥檃ctions ordinaires suppl茅mentaires.
Cette r茅vision refl猫te une augmentation du flottant public de la soci茅t茅 脿 47,7 millions de dollars (3 224 152 actions non affili茅es 脿 14,80 dollars par action) au 20 juin 2025, ce qui 茅l猫ve la limite d鈥櫭﹎ission d鈥檜n tiers autoris茅e par l鈥橧nstruction G茅n茅rale I.B.6 du Formulaire S-3. Au cours des 12 mois pr茅c茅dents, Aptevo a d茅j脿 vendu des actions pour un montant de 7,87 millions de dollars dans le cadre de l鈥橝TM, laissant une capacit茅 nouvellement divulgu茅e de 8,04 millions de dollars avant d鈥檃tteindre le plafond annuel d鈥檈nviron 15,91 millions de dollars.
脌 ce jour, la soci茅t茅 a 茅mis 481 828 actions pour un produit brut de 3,77 millions de dollars, 脿 un prix moyen d鈥檈nviron 7,81 dollars par action. Le dernier cours de cl么ture Nasdaq 茅tait de 4,17 dollars (20 juin 2025), nettement inf茅rieur au prix de r茅f茅rence de 14,80 dollars utilis茅 pour calculer le flottant, ce qui implique une dilution significative si des actions suppl茅mentaires sont vendues aux niveaux actuels.
Aptevo invite les investisseurs 脿 examiner les facteurs de risque dans les prospectus originaux et ant茅rieurs. Aucun changement concernant l鈥檜tilisation des fonds ou la strat茅gie commerciale n鈥檃 茅t茅 communiqu茅 ; le document met uniquement 脿 jour la capacit茅 de vente d鈥檃ctions. D鈥檃utres suppl茅ments seront d茅pos茅s si le flottant augmente suffisamment pour permettre des volumes d鈥櫭﹎ission plus importants.
Aptevo Therapeutics Inc. (NASDAQ: APVO) reichte einen Prospekterg盲nzung vom 20. Juni 2025 ein, der das bestehende At-the-Market (ATM) Aktienprogramm mit Roth Capital Partners aktualisiert. Die Erg盲nzung erh枚ht die verbleibende Kapazit盲t unter der Form S-3 Shelf-Registrierung auf bis zu 8,04 Millionen US-Dollar zus盲tzlicher Stammaktien.
Die Anpassung spiegelt einen Anstieg des 枚ffentlichen Streubesitzes des Unternehmens auf 47,7 Millionen US-Dollar (3.224.152 nicht verbundene Aktien zu je 14,80 US-Dollar) zum 20. Juni 2025 wider, was das ein Drittel Emissionslimit gem盲脽 der Allgemeinen Anweisung I.B.6 des Formulars S-3 anhebt. Im vorangegangenen 12-Monats-Zeitraum hat Aptevo bereits Aktien im Wert von 7,87 Millionen US-Dollar unter dem ATM verkauft, wodurch die neu ausgewiesene Kapazit盲t von 8,04 Millionen US-Dollar vor Erreichen der 12-Monats-Grenze von etwa 15,91 Millionen US-Dollar verbleibt.
Bis heute hat das Unternehmen 481.828 Aktien ausgegeben und dabei Bruttoerl枚se von 3,77 Millionen US-Dollar zu einem durchschnittlichen Preis von etwa 7,81 US-Dollar pro Aktie erzielt. Der letzte Nasdaq-Schlusskurs lag bei 4,17 US-Dollar (20. Juni 2025), deutlich unter dem Referenzpreis von 14,80 US-Dollar, der zur Berechnung des Streubesitzes verwendet wurde, was bei einem Verkauf weiterer Aktien zu aktuellen Kursen eine erhebliche Verw盲sserung bedeuten w眉rde.
Aptevo weist Investoren darauf hin, die Risikofaktoren im urspr眉nglichen und den vorherigen Prospekten zu pr眉fen. Es werden keine 脛nderungen bei der Verwendung der Erl枚se oder der Gesch盲ftsstrategie offengelegt; das Dokument aktualisiert ausschlie脽lich die Verkaufskapazit盲t der Aktien. Weitere Erg盲nzungen werden eingereicht, wenn der Streubesitz ausreichend steigt, um h枚here Emissionsvolumina zu erm枚glichen.
- Enhanced financing flexibility: Raising remaining ATM capacity to $8.0 million provides additional liquidity without the complexity of a full follow-on offering.
- Potential dilution: Additional issuances at the recent $4.17 price could increase outstanding shares by roughly 1.9 million (鈮�60% of float), pressuring EPS and ownership percentages.
- Signal of continuing cash needs: Reliance on equity sales indicates ongoing operating losses and the absence of non-dilutive funding alternatives.
Insights
TL;DR: APVO boosts ATM capacity to $8.0 M; dilution risk elevated as market price falls to $4.17.
The filing is a mechanics-driven update that raises the remaining headroom under the ATM program after the public float rose. While the incremental $8 million is modest in absolute terms, it equates to roughly 19% of current market cap given the depressed share price, so execution could materially dilute existing holders. Management鈥檚 continued reliance on equity sales signals ongoing capital needs typical for pre-revenue biotech firms. No new financial metrics or strategic shifts are revealed, and use of proceeds presumably remains working capital and R&D. Overall sentiment: mildly negative due to dilution, though maintaining financing flexibility is a positive.
TL;DR: Additional $8 M ATM headroom supports liquidity but underscores cash-burn pressures.
Aptevo鈥檚 pipeline progress is not addressed here; the filing is purely capital-markets oriented. However, the decision to enlarge the ATM suggests limited near-term catalysts to support alternative, less dilutive funding. With shares down ~72% from the $14.80 reference, each ATM draw could be highly dilutive. Investors should weigh the benefit of extended cash runway versus potential value erosion. Without fresh clinical data, the market could treat further issuances as a negative signal. Impact: modest but noteworthy, particularly for dilution-sensitive biotech investors.
Aptevo Therapeutics Inc. (NASDAQ: APVO) ha depositato un supplemento al prospetto datato 20 giugno 2025 che aggiorna il suo programma azionario at-the-market (ATM) esistente con Roth Capital Partners. Il supplemento aumenta la capacit脿 residua disponibile sotto la registrazione a scaffale Form S-3 fino a 8,04 milioni di dollari di azioni ordinarie aggiuntive.
L鈥檃deguamento riflette un aumento del flottante pubblico della societ脿 a 47,7 milioni di dollari (3.224.152 azioni non affiliate a 14,80 dollari per azione) al 20 giugno 2025, il che innalza il limite di emissione di un terzo consentito dall鈥橧struzione Generale I.B.6 del Form S-3. Nel periodo di 12 mesi precedente Aptevo ha gi脿 venduto azioni per un valore di 7,87 milioni di dollari nell鈥檃mbito dell鈥橝TM, lasciando una capacit脿 rimanente di 8,04 milioni di dollari prima di raggiungere il tetto annuale di circa 15,91 milioni di dollari.
Ad oggi, la societ脿 ha emesso 481.828 azioni per un ricavo lordo di 3,77 milioni di dollari a un prezzo medio di circa 7,81 dollari per azione. Il prezzo di chiusura pi霉 recente al Nasdaq 猫 stato di 4,17 dollari (20 giugno 2025), decisamente inferiore al prezzo di riferimento di 14,80 dollari usato per calcolare il flottante, implicando una diluizione significativa se ulteriori azioni venissero vendute ai livelli attuali.
Aptevo invita gli investitori a esaminare i fattori di rischio contenuti nel prospetto originale e in quelli precedenti. Non sono state apportate modifiche all鈥檜so dei proventi o alla strategia aziendale; il documento aggiorna esclusivamente la capacit脿 di vendita delle azioni. Ulteriori supplementi saranno depositati se il flottante aumenter脿 sufficientemente da consentire volumi di emissione maggiori.
Aptevo Therapeutics Inc. (NASDAQ: APVO) present贸 un suplemento al prospecto con fecha 20 de junio de 2025 que actualiza su programa de acciones at-the-market (ATM) existente con Roth Capital Partners. El suplemento incrementa la capacidad restante disponible bajo el registro en estanter铆a Formulario S-3 hasta 8,04 millones de d贸lares adicionales en acciones comunes.
Este ajuste refleja un aumento en el flotante p煤blico de la compa帽铆a a 47,7 millones de d贸lares (3.224.152 acciones no afiliadas a 14,80 d贸lares por acci贸n) al 20 de junio de 2025, lo que eleva el l铆mite de emisi贸n de un tercio permitido por la Instrucci贸n General I.B.6 del Formulario S-3. En los 12 meses anteriores, Aptevo ya vendi贸 acciones por un valor de 7,87 millones de d贸lares bajo el ATM, dejando una capacidad disponible de 8,04 millones de d贸lares antes de alcanzar el l铆mite anual aproximado de 15,91 millones de d贸lares.
Hasta la fecha, la empresa ha emitido 481.828 acciones para obtener ingresos brutos de 3,77 millones de d贸lares a un precio promedio de aproximadamente 7,81 d贸lares por acci贸n. El 煤ltimo precio de cierre en Nasdaq fue de 4,17 d贸lares (20 de junio de 2025), considerablemente por debajo del precio de referencia de 14,80 d贸lares utilizado para calcular el flotante, lo que implica una diluci贸n significativa si se venden m谩s acciones a los niveles actuales.
Aptevo advierte a los inversores que revisen los factores de riesgo en el prospecto original y en los anteriores. No se han divulgado cambios en el uso de los ingresos ni en la estrategia comercial; el documento solo actualiza la capacidad de venta de acciones. Se presentar谩n suplementos futuros si el flotante aumenta lo suficiente para permitir mayores vol煤menes de emisi贸n.
Aptevo Therapeutics Inc. (NASDAQ: APVO)電� 2025雲� 6鞗� 20鞚检瀽 韴瀽靹る獏靹� 氤挫订靹滊ゼ 鞝滌稖頃橃棳 Roth Capital Partners鞕�鞚� 旮办〈 ATM(At-the-Market) 欤检嫕 頂勲攴鸽灗鞚� 鞐呺嵃鞚错姼頄堨姷雼堧嫟. 鞚� 氤挫订靹滊姅 Form S-3 靹犽皹 霌彪 頃橃棎靹� 雮晞鞛堧姅 鞖╇焿鞚� 於旉皜 氤错喌欤� 斓滊寑 804毵� 雼煬旯岇 歃濌皜鞁滌及鞀惦媹雼�.
鞚� 臁办爼鞚� 2025雲� 6鞗� 20鞚� 旮办 須岇偓鞚� 瓿店皽 鞙犿喌 欤检嫕靾橁皜 4,770毵� 雼煬(牍勱硠鞐挫偓 欤检嫕 3,224,152欤�, 欤茧嫻 14.80雼煬)搿� 歃濌皜頄堨潓鞚� 氚橃榿頃橂┌, 鞚措姅 Form S-3鞚� 鞚茧皹 歆�旃� I.B.6鞐� 鞚橅暣 項堨毄霅� 1/3 氚滍枆 頃滊弰毳� 靸來枼鞁滍偟雼堧嫟. 歆�雮� 12臧滌洈 霃欖晥 Aptevo電� 鞚措 ATM鞚� 韱淀暣 787毵� 雼煬 靸侂嫻鞚� 欤检嫕鞚� 韺愲Г頄堨溂氅�, 鞚挫棎 霐半澕 12臧滌洈 頃滊弰 鞎� 1,591毵� 雼煬鞐� 霃勲嫭頃橁赴 鞝勱箤歆� 靸堧 瓿店皽霅� 鞖╇焿鞚� 804毵� 雼煬鞛呺媹雼�.
順勳灛旯岇 須岇偓電� 481,828欤�毳� 氚滍枆頃橃棳 齑� 377毵� 雼煬鞚� 靾橃澋鞚� 鞓牳鞙茧┌, 欤茧嫻 韽夑窢 臧�瓴╈潃 鞎� 7.81雼煬鞛呺媹雼�. 2025雲� 6鞗� 20鞚� 旮办 斓滉芳 雮橃姢雼� 膦呹皜電� 4.17雼煬搿�, 鞙犿喌 欤检嫕 瓿勳偘鞐� 靷毄霅� 旮办 臧�瓴� 14.80雼煬氤措嫟 順勳爛頌� 雮晞, 順勳灛 臧�瓴� 靾橃鞐愳劀 於旉皜 欤检嫕鞚� 韺愲Г霅� 瓴届毎 靸侂嫻頃� 頋劃 須臣臧� 鞓堨儊霅╇媹雼�.
Aptevo電� 韴瀽鞛愲摛鞐愱矊 鞗愲掣 氚� 鞚挫爠 韴瀽靹る獏靹滌棎 韽暔霅� 鞙勴棙 鞖旍唽毳� 瓴�韱犿暊 瓴冹潉 甓岅碃頃╇媹雼�. 靾橃澋 靷毄觳橂倶 靷梾 鞝勲灥鞐� 雽�頃� 氤�瓴� 靷暛鞚� 鞐嗢溂氅�, 鞚� 氍胳劀電� 雼 欤检嫕 韺愲Г 鞖╇焿鞚� 鞐呺嵃鞚错姼頃� 瓴冹瀰雼堧嫟. 頄ロ泟 鞙犿喌 欤检嫕鞚� 於╇秳頌� 歃濌皜頃橃棳 雿� 雴掛潃 氚滍枆霟夓澊 項堨毄霅橂┐ 於旉皜 氤挫订靹滉皜 鞝滌稖霅� 鞓堨爼鞛呺媹雼�.
Aptevo Therapeutics Inc. (NASDAQ : APVO) a d茅pos茅 un suppl茅ment au prospectus dat茅 du 20 juin 2025, mettant 脿 jour son programme d鈥檃ctions at-the-market (ATM) existant avec Roth Capital Partners. Ce suppl茅ment augmente la capacit茅 restante disponible dans le cadre de l鈥檈nregistrement sur 茅tag猫re Formulaire S-3 jusqu鈥櫭� 8,04 millions de dollars d鈥檃ctions ordinaires suppl茅mentaires.
Cette r茅vision refl猫te une augmentation du flottant public de la soci茅t茅 脿 47,7 millions de dollars (3 224 152 actions non affili茅es 脿 14,80 dollars par action) au 20 juin 2025, ce qui 茅l猫ve la limite d鈥櫭﹎ission d鈥檜n tiers autoris茅e par l鈥橧nstruction G茅n茅rale I.B.6 du Formulaire S-3. Au cours des 12 mois pr茅c茅dents, Aptevo a d茅j脿 vendu des actions pour un montant de 7,87 millions de dollars dans le cadre de l鈥橝TM, laissant une capacit茅 nouvellement divulgu茅e de 8,04 millions de dollars avant d鈥檃tteindre le plafond annuel d鈥檈nviron 15,91 millions de dollars.
脌 ce jour, la soci茅t茅 a 茅mis 481 828 actions pour un produit brut de 3,77 millions de dollars, 脿 un prix moyen d鈥檈nviron 7,81 dollars par action. Le dernier cours de cl么ture Nasdaq 茅tait de 4,17 dollars (20 juin 2025), nettement inf茅rieur au prix de r茅f茅rence de 14,80 dollars utilis茅 pour calculer le flottant, ce qui implique une dilution significative si des actions suppl茅mentaires sont vendues aux niveaux actuels.
Aptevo invite les investisseurs 脿 examiner les facteurs de risque dans les prospectus originaux et ant茅rieurs. Aucun changement concernant l鈥檜tilisation des fonds ou la strat茅gie commerciale n鈥檃 茅t茅 communiqu茅 ; le document met uniquement 脿 jour la capacit茅 de vente d鈥檃ctions. D鈥檃utres suppl茅ments seront d茅pos茅s si le flottant augmente suffisamment pour permettre des volumes d鈥櫭﹎ission plus importants.
Aptevo Therapeutics Inc. (NASDAQ: APVO) reichte einen Prospekterg盲nzung vom 20. Juni 2025 ein, der das bestehende At-the-Market (ATM) Aktienprogramm mit Roth Capital Partners aktualisiert. Die Erg盲nzung erh枚ht die verbleibende Kapazit盲t unter der Form S-3 Shelf-Registrierung auf bis zu 8,04 Millionen US-Dollar zus盲tzlicher Stammaktien.
Die Anpassung spiegelt einen Anstieg des 枚ffentlichen Streubesitzes des Unternehmens auf 47,7 Millionen US-Dollar (3.224.152 nicht verbundene Aktien zu je 14,80 US-Dollar) zum 20. Juni 2025 wider, was das ein Drittel Emissionslimit gem盲脽 der Allgemeinen Anweisung I.B.6 des Formulars S-3 anhebt. Im vorangegangenen 12-Monats-Zeitraum hat Aptevo bereits Aktien im Wert von 7,87 Millionen US-Dollar unter dem ATM verkauft, wodurch die neu ausgewiesene Kapazit盲t von 8,04 Millionen US-Dollar vor Erreichen der 12-Monats-Grenze von etwa 15,91 Millionen US-Dollar verbleibt.
Bis heute hat das Unternehmen 481.828 Aktien ausgegeben und dabei Bruttoerl枚se von 3,77 Millionen US-Dollar zu einem durchschnittlichen Preis von etwa 7,81 US-Dollar pro Aktie erzielt. Der letzte Nasdaq-Schlusskurs lag bei 4,17 US-Dollar (20. Juni 2025), deutlich unter dem Referenzpreis von 14,80 US-Dollar, der zur Berechnung des Streubesitzes verwendet wurde, was bei einem Verkauf weiterer Aktien zu aktuellen Kursen eine erhebliche Verw盲sserung bedeuten w眉rde.
Aptevo weist Investoren darauf hin, die Risikofaktoren im urspr眉nglichen und den vorherigen Prospekten zu pr眉fen. Es werden keine 脛nderungen bei der Verwendung der Erl枚se oder der Gesch盲ftsstrategie offengelegt; das Dokument aktualisiert ausschlie脽lich die Verkaufskapazit盲t der Aktien. Weitere Erg盲nzungen werden eingereicht, wenn der Streubesitz ausreichend steigt, um h枚here Emissionsvolumina zu erm枚glichen.
|
|
|
PROSPECTUS SUPPLEMENT (To Prospectus dated February 26, 2025) |
|
Filed Pursuant to Rule 424(b)(5) Registration No. 333-284969 |
Up to $8,037,381
This prospectus supplement amends and supplements the information in the prospectus, dated February 26, 2025, filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-284969) (the “Registration Statement”), as previously supplemented by our prospectus supplements, dated April 28, 2025 (the “April 28 Prospectus Supplement” and together with the Registration Statement, the “Original Prospectus”), April 29, 2025 (collectively with the Original Prospectus, the “April 29 Prospectus”) and May 22, 2025 (collectively with the April 29 Prospectus, the “Prior Prospectus”), relating to the offer and sale of a number of shares of our common stock, $0.001 par value per share, having an aggregate offering price of up to $50,000,000 (“Shares”), pursuant to that certain At The Market Offering Agreement we previously entered into with Roth Capital Partners ("Roth") on April 28, 2025 (the “Sales Agreement”). This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without and may only be delivered or utilized in connection with, the Prior Prospectus and any future amendments or supplements thereto.
As of the date of this prospectus supplement, we have sold 481,828 shares of our common stock at an aggregate gross offering price of $7.81 pursuant to the Sales Agreement and the Prior Prospectus for aggregate gross sale proceeds of $3,765,143. We are filing this prospectus supplement to amend the Prior Prospectus to increase the amount we may offer and sell under the registration statement of which this prospectus supplement and the Prior Prospectus form a part following an increase in the aggregate market value of issued and outstanding shares of our common stock held by non-affiliates (our “Public Float”).
Pursuant to General Instruction I.B.6 of Form S-3, in no event may we sell, pursuant to the registration statement of which this prospectus supplement and the Prior Prospectus form a part, securities in a public primary offering with a value exceeding one-third of our Public Float in any 12-month period, so long as our Public Float remains below $75,000,000. Our Public Float as of June 20, 2025 was $47,717,450 based on 3,224,152 shares of our common stock issued and outstanding and held by non-affiliates on June 20, 2025, and a price per share of $14.80 as of April 23, 2025, which is a date within 60 days prior to the filing date of this prospectus supplement. As of the date hereof, we have sold securities with an aggregate market value of $7,868,436 pursuant to General Instruction I.B.6 of Form S-3 during the prior 12-month period that ends on and includes the date hereof.
As a result of the limitations of General Instruction I.B.6 of Form S-3, and in accordance with the terms of the Sales Agreement, we may currently offer and sell additional shares of our common stock having an aggregate offering price of up to $8,037,381 from time to time through Roth as sales agent. If our Public Float increases such that we may sell a greater amount of shares of our common stock under the Sales Agreement and the registration statement of which this prospectus supplement and the Prior Prospectus form a part, we will file another prospectus supplement prior to making such sales.
Our common stock is listed on The Nasdaq Capital Market under the symbol “APVO.” The last reported sale price of our common stock on June 20, 2025, was $4.17 per share.
Investing in our securities involves risks. See “Risk Factors” on page S-7 of the Original Prospectus, and in the filings with the Securities and Exchange Commission that are incorporated by reference into the Prior Prospectus and this prospectus supplement, for certain risks you should consider. You should read all the information set forth in this prospectus supplement and the Prior Prospectus, as well as the documents incorporated by reference herein and the Prior Prospectus, carefully before you make your investment decision.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prior Prospectus, this prospectus supplement or the accompanying prospectus are truthful or complete. Any representation to the contrary is a criminal offense.
Roth Capital Partners
The date of this prospectus supplement is June 20, 2025
Source:
FAQ
Why did Aptevo Therapeutics (APVO) file a new prospectus supplement on June 20, 2025?
How much stock has APVO already sold under its ATM program?
What is Aptevo鈥檚 current public float and why is it important?
What is the dilution impact if APVO issues the full $8.04 million at $4.17 per share?
Where is APVO鈥檚 common stock listed and what was the last closing price?
